Autonomix Medical, Inc. (NASDAQ: AMIX) Reviews Positive Results Seen in Pancreatic Cancer Pain Trial in Virtual Investor “What This Means” Segment Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses preliminary positive results from the first five “lead-in” patients in the Company’s ongoing human clinical trial THE...

Autonomix Announces Positive Topline Results from First Five Lead-In Patients in Ongoing Human Clinical Trial The first five patients successfully completed protocols with no immediate procedural-related complications or significant adverse events; Pain relief for responder group was experienced as quick as 1...

Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial Company plans to release topline results from “lead-in” patients (n=5) imminently THE WOODLANDS, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the...

Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, March 14, 2024 (GLOBE NEWSWIRE) --...

Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, March 06, 2024 (GLOBE NEWSWIRE) --...